Intravenous immunoglobulin therapy in intractable childhood epilepsy: Open-label study and review of the literature

Abstract Our aim was to investigate the long term effectiveness of intravenous immunoglobulin (IVIG) against intractable childhood epilepsy in the era of new antiepileptics and to determine the predictors of a favorable response in a prospective open-label add-on study. Of thirty-seven 9.9 ± 0.9-yea...

Full description

Saved in:
Bibliographic Details
Published inEpilepsy & behavior Vol. 17; no. 1; pp. 90 - 94
Main Authors Mikati, Mohamad A, Kurdi, Rana, El-Khoury, Ziad, Rahi, Amal, Raad, Wissam
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.01.2010
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Our aim was to investigate the long term effectiveness of intravenous immunoglobulin (IVIG) against intractable childhood epilepsy in the era of new antiepileptics and to determine the predictors of a favorable response in a prospective open-label add-on study. Of thirty-seven 9.9 ± 0.9-year-old patients (11 with partial seizures, 26 with generalized seizures of whom 9 had West syndrome and 17 Lennox–Gastaut syndrome) followed for 15 ± 3 months, 43% had a >50% decrease in seizures (including 15% seizure free, 229 ± 58 compared with 104 ± 3 seizures/month, P = 0.035: generalized 246 ± 318 to 117 ± 200, P = 0.025, partial 191 ± 437 to 72 ± 179, P > 0.05; power = 0.2). Males were more likely to respond than females ( P = 0.011, odds ratio = 9.3). Review of the literature revealed nine other articles reporting efficacy of IVIG against epileptic seizures. Only one other used statistical methods and, unlike ours, showed only a trend toward seizure frequency reduction without achieving statistical significance, presumably because it was underpowered. These results indicate large-scale controlled studies of IVIG in epilepsy are still needed.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ISSN:1525-5050
1525-5069
DOI:10.1016/j.yebeh.2009.10.020